Notice Regarding Cancellation of Treasury Stock

Overview of Capital Policy

At the Board of Directors meeting held on March 13, 2026, Hisamitsu Pharmaceutical Co., Inc. resolved to cancel 4,763,348 shares of treasury stock held by the company in accordance with Article 178 of the Companies Act. This amount corresponds to 6.34% of the total outstanding shares before cancellation. The scheduled cancellation date is May 12, 2026, after which the total number of outstanding shares will be 70,401,547 shares. The cancellation is conditional upon approval of agenda items including share consolidation at the extraordinary general meeting of shareholders scheduled for April 17, 2026.

Impact on Shareholders and Future Outlook

This treasury stock cancellation will reduce the number of outstanding shares, which is expected to enhance the value per share. The cancellation covers all treasury shares held and aims to improve capital efficiency. It is part of procedures related to share consolidation and the abolition of the designation of unit shares. The cancellation will be implemented following approval at the extraordinary general shareholders meeting. Investors should pay close attention to the resolutions at upcoming shareholders meetings.